These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 37604268)

  • 1. Progression of non-alcoholic fatty liver disease and long-term outcomes: A nationwide paired liver biopsy cohort study.
    Simon TG; Roelstraete B; Hagström H; Loomba R; Ludvigsson JF
    J Hepatol; 2023 Dec; 79(6):1366-1373. PubMed ID: 37604268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort.
    Simon TG; Roelstraete B; Khalili H; Hagström H; Ludvigsson JF
    Gut; 2021 Jul; 70(7):1375-1382. PubMed ID: 33037056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort.
    Simon TG; Roelstraete B; Hagström H; Sundström J; Ludvigsson JF
    Gut; 2022 Sep; 71(9):1867-1875. PubMed ID: 34489307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-alcoholic fatty liver disease in children and young adults is associated with increased long-term mortality.
    Simon TG; Roelstraete B; Hartjes K; Shah U; Khalili H; Arnell H; Ludvigsson JF
    J Hepatol; 2021 Nov; 75(5):1034-1041. PubMed ID: 34224779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study.
    Ebrahimi F; Hagström H; Sun J; Bergman D; Shang Y; Yang W; Roelstraete B; Ludvigsson JF
    J Hepatol; 2023 Dec; 79(6):1374-1384. PubMed ID: 37647992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular disease risk in paediatric and young adult non-alcoholic fatty liver disease.
    Simon TG; Roelstraete B; Alkhouri N; Hagström H; Sundström J; Ludvigsson JF
    Gut; 2023 Mar; 72(3):573-580. PubMed ID: 36522149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer Risk in Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study.
    Simon TG; Roelstraete B; Sharma R; Khalili H; Hagström H; Ludvigsson JF
    Hepatology; 2021 Nov; 74(5):2410-2423. PubMed ID: 33811766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.
    Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Hultcrantz R; Kechagias S
    J Hepatol; 2017 Dec; 67(6):1265-1273. PubMed ID: 28803953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis.
    Aminian A; Al-Kurd A; Wilson R; Bena J; Fayazzadeh H; Singh T; Albaugh VL; Shariff FU; Rodriguez NA; Jin J; Brethauer SA; Dasarathy S; Alkhouri N; Schauer PR; McCullough AJ; Nissen SE
    JAMA; 2021 Nov; 326(20):2031-2042. PubMed ID: 34762106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.
    McPherson S; Hardy T; Henderson E; Burt AD; Day CP; Anstee QM
    J Hepatol; 2015 May; 62(5):1148-55. PubMed ID: 25477264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of Severe Infection in Patients With Biopsy-proven Nonalcoholic Fatty Liver Disease - A Population-based Cohort Study.
    Ebrahimi F; Simon TG; Hagström H; Söderling J; Wester A; Roelstraete B; Ludvigsson JF
    Clin Gastroenterol Hepatol; 2023 Dec; 21(13):3346-3355.e19. PubMed ID: 37245712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.
    Vilar-Gomez E; Calzadilla-Bertot L; Wai-Sun Wong V; Castellanos M; Aller-de la Fuente R; Metwally M; Eslam M; Gonzalez-Fabian L; Alvarez-Quiñones Sanz M; Conde-Martin AF; De Boer B; McLeod D; Hung Chan AW; Chalasani N; George J; Adams LA; Romero-Gomez M
    Gastroenterology; 2018 Aug; 155(2):443-457.e17. PubMed ID: 29733831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term major adverse liver outcomes in 1,260 patients with non-cirrhotic NAFLD.
    Akbari C; Dodd M; Stål P; Nasr P; Ekstedt M; Kechagias S; Vessby J; Rorsman F; Zhang X; Wang T; Jemielita T; Fernandes G; Engel SS; Hagström H; Shang Y
    JHEP Rep; 2024 Feb; 6(2):100915. PubMed ID: 38293684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease.
    Kleiner DE; Brunt EM; Wilson LA; Behling C; Guy C; Contos M; Cummings O; Yeh M; Gill R; Chalasani N; Neuschwander-Tetri BA; Diehl AM; Dasarathy S; Terrault N; Kowdley K; Loomba R; Belt P; Tonascia J; Lavine JE; Sanyal AJ;
    JAMA Netw Open; 2019 Oct; 2(10):e1912565. PubMed ID: 31584681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease.
    Nascimbeni F; Bedossa P; Fedchuk L; Pais R; Charlotte F; Lebray P; Poynard T; Ratziu V;
    J Hepatol; 2020 May; 72(5):828-838. PubMed ID: 31862486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
    APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inevitability of disease recurrence after liver transplantation for NAFLD cirrhosis.
    Villeret F; Dharancy S; Erard D; Abergel A; Barbier L; Besch C; Boillot O; Boudjema K; Coilly A; Conti F; Corpechot C; Duvoux C; Faitot F; Faure S; Francoz C; Giostra E; Gugenheim J; Hardwigsen J; Hilleret MN; Hiriart JB; Houssel-Debry P; Kamar N; Lassailly G; Latournerie M; Pageaux GP; Samuel D; Vanlemmens C; Saliba F; Dumortier J
    JHEP Rep; 2023 Mar; 5(3):100668. PubMed ID: 36852108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease.
    Henson JB; Simon TG; Kaplan A; Osganian S; Masia R; Corey KE
    Aliment Pharmacol Ther; 2020 Apr; 51(7):728-736. PubMed ID: 32043602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daily Aspirin Use Associated With Reduced Risk For Fibrosis Progression In Patients With Nonalcoholic Fatty Liver Disease.
    Simon TG; Henson J; Osganian S; Masia R; Chan AT; Chung RT; Corey KE
    Clin Gastroenterol Hepatol; 2019 Dec; 17(13):2776-2784.e4. PubMed ID: 31077838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease.
    Sanyal AJ; Williams SA; Lavine JE; Neuschwander-Tetri BA; Alexander L; Ostroff R; Biegel H; Kowdley KV; Chalasani N; Dasarathy S; Diehl AM; Loomba R; Hameed B; Behling C; Kleiner DE; Karpen SJ; Williams J; Jia Y; Yates KP; Tonascia J
    J Hepatol; 2023 Apr; 78(4):693-703. PubMed ID: 36528237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.